Page 4 | Certara

Announcement

Thieme integrates Certara Chemaxon’s new generation chemical sketcher, Marvin, into its chemical databases Science of Synthesis and Pharmaceutical Substances

Latest version of Marvin is more accurate and user-friendly for Chemical Database Subscribers Stuttgart, Germany…

Danielle PillsburyApril 14, 2026

Webinar

RAPS sponsored webinar: From Silos to Synergy: A Practical Guide to Integrating Regulatory Writing and Operations for Seamless Submissions

CertaraApril 13, 2026

Conference

EFMC International Symposium on Medicinal Chemistry 2026

CertaraApril 13, 2026

On-Demand Webinar

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

Learn how model-informed strategies support ADC labeling, dose optimization, and market access through integrated evidence…

CertaraApril 10, 2026

Webinar

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

CertaraApril 10, 2026

Press Release

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

Radnor, Pa. — April 9, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in…

Danielle PillsburyApril 9, 2026

Blog

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Learn how key PK parameters such as Cmax, AUC, clearance, half life, and volume of…

CertaraApril 9, 2026

Announcement

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

Dr. Britta Wagenhuber has joined the company as Head of Quantitative Systems Pharmacology (QSP) Consultancy.

CertaraApril 8, 2026

Conference

AMWA NorCal Pacific Coast Conference

Danielle PillsburyApril 8, 2026

Case Study

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

HUTCHMED was preparing a New Drug Application (NDA) submission for FRUZAQLA® (fruquintinib) a drug developed…

CertaraApril 7, 2026